Plain-English translation of NCT04385290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding two medications—midostaurin and gemtuzumab ozogamicin—to standard chemotherapy works better than chemotherapy alone for newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. The trial has two main phases: the first determines the safest doses of these medications to use, and the second compares the combination treatment to standard therapy in different groups of patients based on their specific genetic mutations.
AML remains a deadly disease, and even patients with the better-prognosis genetic forms often relapse. This medication combination targets specific mutations known to drive the cancer and help it resist treatment, so researchers hope it may improve survival and reduce the chance of relapse.
You likely qualify if…
You likely don't qualify if…
You would receive intensive inpatient chemotherapy (two drugs given over several days) combined with the two study medications. The first phase of the trial tests different dose levels to find the safest and most effective combination; the second phase then tests this recommended dose against standard chemotherapy alone. You would need hospital stays for treatment cycles and multiple follow-up visits with blood tests and scans to monitor your response and side effects over several months.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany